News

Keep up with the latest news from the NCI Center for Biomedical Informatics and Information Technology (CBIIT) and the data science communities.

An international team of researchers combined genomics, biopsy results, and artificial intelligence (AI) to track prostate cancer over time. Learn more about these “evolvability” metrics and how they could someday help predict cancer re-occurrence.

If you’re working with NIH genomic data, you’ll need to be aware of some new security requirements for data management and access that take effect on January 25, 2025. Learn more about how this could impact your work.

Want to pursue a career opportunity in data science with NCI? Browse through federal and contractor roles, fellowships, and internships in our recently launched employment section!

NIH has a new funding opportunity to help you develop robust, re-usable scientific software and tools to advance cancer research.

NCI-funded researchers are blending mathematics with machine learning to refine cancer treatment. In the future, this kind of virtual tumor model could help to further personalize care for people with cancer.

NCI researchers are using artificial intelligence (AI) to uncover additional information from medical images. This helps them not only to diagnose cancer but also to predict how it will progress and if it will re-occur.

These APIs aim to enhance data accessibility and integration for childhood cancer research, leading to advancements in treatments for pediatric cancer patients.

Are you a cancer biology investigator? NCI wants to hear about your experiences developing and implementing data management and sharing plans. Share your feedback by July 26, 2024.

A new, scalable, machine learning model is helping scientists model thousands of transcription factors and genes in the human genome, providing new information on these genes and how they work/change over time.

Learn how supercomputing and cancer research expertise helped transform a previously complex, ‘undruggable’ target into a promising, first-in-class medication. Researchers are now testing it in human trials.